Xperi - XPER Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xperi in the last year. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XPER shares.
View XPER analyst ratings or view top-rated stocks.

3 analysts have issued 12 month price targets for Xperi's shares. Their XPER share price forecasts range from $19.00 to $30.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 136.9% from the stock's current price.
View analysts price targets for XPER or view top-rated stocks among Wall Street analysts.

Xperi's stock was trading at $18.91 at the beginning of the year. Since then, XPER stock has decreased by 46.4% and is now trading at $10.13.
View the best growth stocks for 2022 here.

Xperi saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 1,460,000 shares, an increase of 17.7% from the October 15th total of 1,240,000 shares. Based on an average daily volume of 352,600 shares, the days-to-cover ratio is currently 4.1 days.
View Xperi's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our XPER earnings forecast.

Xperi Inc. (NASDAQ:XPER) released its quarterly earnings results on Sunday, November, 7th. The semiconductor company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.19. The semiconductor company earned $219.38 million during the quarter, compared to analyst estimates of $223.84 million. During the same quarter in the previous year, the company earned ($0.28) earnings per share.

Xperi announced a quarterly dividend on Friday, July 29th. Shareholders of record on Monday, August 29th will be paid a dividend of $0.05 per share on Monday, September 19th. This represents a $0.20 annualized dividend and a yield of 1.97%. The ex-dividend date of this dividend is Friday, August 26th.
Read our dividend analysis for XPER.

Xperi updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $490.00 million-$510.00 million, compared to the consensus revenue estimate of $499.43 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xperi investors own include Intel (INTC), QUALCOMM (QCOM), AT&T (T), Cisco Systems (CSCO), NVIDIA (NVDA), Boeing (BA), Gilead Sciences (GILD), Micron Technology (MU), Pfizer (PFE) and Verizon Communications (VZ).

Xperi trades on the NASDAQ under the ticker symbol "XPER."

Xperi's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.23%), Vanguard Group Inc. (11.31%), Rubric Capital Management LP (3.70%), Bank of New York Mellon Corp (1.24%), Renaissance Technologies LLC (1.18%) and TSP Capital Management Group LLC (0.81%). Insiders that own company stock include Christopher A Seams, Daniel M Moloney, David C Habiger, Geir Skaaden, Jon Kirchner, Laura Durr, Matthew Milne, Paul E Davis, Paul E Davis and Samir Armaly.
View institutional ownership trends.

Shares of XPER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XPER stock can currently be purchased for approximately $10.13.

Xperi (NASDAQ:XPER) has a market capitalization of $425.66 million.

The company employs 1,800 workers across the globe.

Xperi's mailing address is 3025 ORCHARD PARKWAY, SAN JOSE CA, 95134. The official website for the company is www.xperi.com. The semiconductor company can be reached via phone at (408) 321-6000, via email at ir@xperi.com, or via fax at 408-321-8257.